Related Experiment Video
Updated: Jun 12, 2026
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Left atrial appendage closure
Inder M Singh1, David R Holmes
1Mayo Clinic, Rochester, MN 55905, USA. singh.inder@mayo.edu
Insights
Atrial fibrillation stroke prevention is crucial. Left atrial appendage closure devices offer a promising alternative to anticoagulants like warfarin, improving stroke risk management.
Area of Science:
- Cardiology
- Vascular Medicine
- Medical Devices
Background:
- Atrial fibrillation (AF) poses a significant stroke risk, necessitating effective prevention strategies.
- Current anticoagulants like warfarin have limitations, including narrow therapeutic windows and bleeding risks.
- Thromboemboli often originate from the left atrial appendage (LAA), making LAA exclusion a key target.
Purpose of the Study:
- To review the role of left atrial appendage (LAA) closure devices in stroke prevention for atrial fibrillation (AF) patients.
- To evaluate LAA closure as an alternative or adjunct to pharmacotherapy.
- To discuss the current status and future potential of LAA closure technologies.
Main Methods:
- Review of existing clinical data and randomized trials on LAA closure devices.
- Analysis of device efficacy and safety compared to pharmacologic stroke prevention.
- Assessment of surgical LAA exclusion techniques.
Main Results:
- Percutaneous LAA closure devices are emerging as viable options for stroke prevention in AF.
- The WATCHMAN device shows promising randomized data.
- Other LAA closure devices are in various stages of development.
Conclusions:
- Left atrial appendage closure represents a significant advancement in AF stroke prevention.
- Device-based LAA closure offers a compelling alternative to traditional anticoagulation.
- Continued research and development are essential for optimizing LAA closure therapies.
Abstract:
Stroke prevention is the primary goal in atrial fibrillation (AF) given its clinical and socioeconomic impact. With AF, the prevalence of thromboembolic stroke continues to rise and there is an urgent need to develop better strategies of stroke prevention. Warfarin, although effective when used appropriately, is burdened by underutilization, narrow therapeutic windows, and life-threatening bleeding complications. Novel pharmacologic agents have been plagued by off-target toxicity and only modest improvement in bleeding complications over warfarin. Because most thromboemboli arise from the left atrial appendage (LAA), surgical exclusion of the LAA is often used in AF patients undergoing cardiac surgery. Percutaneous device LAA closure has now been developed as an adjunct and as an alternative to pharmacotherapy in patients with AF. Promising randomized data are available with the WATCHMAN device, while several other devices are in various stages of clinical and preclinical development.
